公开(公告)号：US20090275081A1

公开(公告)日：2009-11-05

申请号：US12363678

申请日：2009-01-30

Applicant: Bhaswati Barat ,  Anna M. Wu

Inventor： Bhaswati Barat ,  Anna M. Wu

IPC: C12P21/00 ,  C12N5/00

CPC classification number: C12P21/02

Abstract: The present invention provides methods of metabolically biotinylating recombinant proteins. Cell lines and specific protein and nucleic acid constructs for use in the methods of the present invention are also provided herein.

Abstract translation: 本发明提供代谢生物素化重组蛋白的方法。 本文还提供了用于本发明方法的细胞系和特异性蛋白质和核酸构建体。

公开(公告)号：US5837821A

公开(公告)日：1998-11-17

申请号：US256156

申请日：1994-06-24

Applicant: Anna M. Wu

Inventor： Anna M. Wu

IPC: C07K16/00 ,  C07K16/30 ,  C07K16/46 ,  C12N1/21 ,  C12N15/13 ,  C12P21/08 ,  C07H21/04 ,  C12N15/10

CPC classification number: C07K16/468 ,  C07K16/00 ,  C07K16/3007 ,  Y10S530/866 ,  Y10S530/867

Abstract: An antigen binding protein construct or "minibody" which includes the VL and VH domains of a native antibody fused to the hinge region and CH3 domain of the immunoglobulin molecule is described. Minibodies are small versions of whole antibodies which encode in a single chain the essential elements of a whole antibody. Minibodies are expressed by host cells transformed with minibody genes.

Abstract translation: PCT No.PCT / US92 / 09347 Sec。 371日期：1994年6月24日 102（e）日期1994年6月24日PCT提交1992年11月4日PCT公布。 第WO94 / 09817号公报 日期1994年5月11日描述了包含与免疫球蛋白分子的铰链区和CH3结构域融合的天然抗体的VL和VH结构域的抗原结合蛋白构建体或“微型体”。 小抗体是在单链中编码整个抗体的基本元件的全部抗体的小版本。 小细胞被用小体细胞基因转化的宿主细胞表达。

公开(公告)号：US09701754B1

公开(公告)日：2017-07-11

申请号：US12788477

申请日：2010-05-27

Applicant: Anna M. Wu ,  John E. Shively ,  Andrew A. Raubitschek ,  Mark A. Sherman ,  Tove Olafsen

Inventor： Anna M. Wu ,  John E. Shively ,  Andrew A. Raubitschek ,  Mark A. Sherman ,  Tove Olafsen

IPC: C07K16/00 ,  C07K16/30

CPC classification number: C07K16/30 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/3007 ,  C07K16/46 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/90 ,  C07K2319/00

Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.

公开(公告)号：US20120283418A1

公开(公告)日：2012-11-08

申请号：US13554306

申请日：2012-07-20

Applicant: Anna M. Wu ,  John E. Shively ,  Andrew A. Raubitschek ,  Mark A. Sherman ,  Tove Olafsen

Inventor： Anna M. Wu ,  John E. Shively ,  Andrew A. Raubitschek ,  Mark A. Sherman ,  Tove Olafsen

IPC: C07K16/00

CPC classification number: C07K16/30 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/3007 ,  C07K16/46 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/90 ,  C07K2319/00

Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.

Abstract translation: 本发明提供重组抗体片段，其包括通过向其C末端添加尾序列而被修饰的可变结构域。 尾序列包含末端半胱氨酸残基和氨基酸间隔基，并且基本上不影响片段的靶结合亲和力。 本发明还提供包含所述抗体片段和药学上可接受的载体的药物组合物，以及使用片段作为递送载体将试剂递送至受试者感兴趣的细胞的方法。 本发明还提供了包含所述抗体片段的组合物，用于体外检测和测量结合片段的靶分子，以及通过使样品与这些组合物接触来确定生物样品中这些靶的存在或量的方法。

公开(公告)号：US07727525B2

公开(公告)日：2010-06-01

申请号：US11741253

申请日：2007-04-27

Applicant: Anna M. Wu ,  Tove Olafsen ,  Andrew A. Raubitschek

Inventor： Anna M. Wu ,  Tove Olafsen ,  Andrew A. Raubitschek

IPC: A61K51/10 ,  A61K49/00 ,  A61K39/395

CPC classification number: C07K16/2887 ,  A61K51/1027 ,  C07K2317/622 ,  C07K2319/30

Abstract: The present invention provides anti-CD20 antibody fragments for use as in vivo imaging probes and as therapeutic moieties for the diagnosis and treatment of NHL.

Abstract translation: 本发明提供用作体内成像探针的抗CD20抗体片段和用于诊断和治疗NHL的治疗部分。

公开(公告)号：US09765155B2

公开(公告)日：2017-09-19

申请号：US13554306

申请日：2012-07-20

Applicant: Anna M. Wu ,  John E. Shively ,  Andrew A. Raubitschek ,  Mark A. Sherman ,  Tove Olafsen

Inventor： Anna M. Wu ,  John E. Shively ,  Andrew A. Raubitschek ,  Mark A. Sherman ,  Tove Olafsen

IPC: A61K39/00 ,  C07K16/46 ,  C07K16/00 ,  C07K16/30 ,  A61K39/395

CPC classification number: C07K16/30 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/3007 ,  C07K16/46 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/90 ,  C07K2319/00

Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.

公开(公告)号：US20120076728A1

公开(公告)日：2012-03-29

申请号：US13263069

申请日：2010-04-07

Applicant: Anna M. Wu ,  Vania E. Kenanova ,  Tove Olafsen

Inventor： Anna M. Wu ,  Vania E. Kenanova ,  Tove Olafsen

IPC: A61K38/38 ,  A61K49/00 ,  A61P35/00 ,  C12N9/96 ,  C07K19/00 ,  A61K51/08 ,  B82Y5/00 ,  B82Y15/00

CPC classification number: C07K14/765 ,  A61K38/00 ,  A61K47/61 ,  A61K47/6889 ,  A61K51/1048 ,  C07K16/42 ,  C07K19/00 ,  C07K2319/30 ,  C07K2319/33 ,  C12N15/115 ,  C12N2310/16

Abstract: This invention provides constructs comprising a protein scaffold, wherein the scaffold comprises Domain III, Domain IIIa, or Domain IIIb of human serum albumin or a polypeptide having substantial sequence identity to the Domain III, the Domain IIIa, or the Domain IIIb; and a targeting moiety in covalent linkage to the protein scaffold; and a therapeutic moiety and/or an imaging moiety in covalent linkage to the protein scaffold. The scaffold can be modified to tune the serum pharmacokinetics of the construct. In addition to methods of making the constructs, therapeutic, imaging and diagnostic uses of the constructs are also provided.

Abstract translation: 本发明提供了包含蛋白质支架的构建体，其中所述支架包含人血清白蛋白的III区，IIIa区或IIIb区，或与III，Domain IIIa或Domain IIIb具有实质序列同一性的多肽; 和与蛋白质支架共价连接的靶向部分; 和与蛋白质支架共价连接的治疗部分和/或成像部分。 可以修饰支架以调节构建体的血清药代动力学。 除了制备构建体的方法之外，还提供了构建体的治疗，成像和诊断用途。

公开(公告)号：US20120020983A9

公开(公告)日：2012-01-26

申请号：US12682032

申请日：2008-10-08

Applicant: Jonathan Braun ,  Lynn K. Gordon ,  Kaori Shimazaki ,  Madhuri Wadehra ,  Kathy A. Kelly ,  Anna M. Wu

Inventor： Jonathan Braun ,  Lynn K. Gordon ,  Kaori Shimazaki ,  Madhuri Wadehra ,  Kathy A. Kelly ,  Anna M. Wu

IPC: A61K39/395 ,  G01N33/53 ,  A61P35/00 ,  C07K16/18

CPC classification number: C07K16/30 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/125 ,  C07K16/28 ,  C07K2316/96 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/00 ,  A61K2300/00

Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.

Abstract translation: 本发明提供了用于治疗或预防衣原体感染和癌症的方法和组合物。 方法和组合物通过干扰衣原体和EMP2之间的相互作用来抑制衣原体进入表达EMP2的宿主细胞。 方法和组合物靶向通过靶向EMP2表达或过表达EMP2核酸和多肽的癌症。

公开(公告)号：US08043830B2

公开(公告)日：2011-10-25

申请号：US12363678

申请日：2009-01-30

Applicant: Bhaswati Barat ,  Anna M. Wu

Inventor： Bhaswati Barat ,  Anna M. Wu

IPC: C12P21/00 ,  C12P21/04

CPC classification number: C12P21/02

Abstract: The present invention provides methods of metabolically biotinylating recombinant proteins. Cell lines and specific protein and nucleic acid constructs for use in the methods of the present invention are also provided herein.

Abstract translation: 本发明提供代谢生物素化重组蛋白的方法。 本文还提供了用于本发明方法的细胞系和特异性蛋白质和核酸构建体。

公开(公告)号：US07939649B2

公开(公告)日：2011-05-10

申请号：US11995586

申请日：2006-09-06

Applicant: Sanjiv S. Gambhir ,  Andreas M. Loening ,  Anna M. Wu

Inventor： Sanjiv S. Gambhir ,  Andreas M. Loening ,  Anna M. Wu

IPC: C07H21/04 ,  C12N5/00

CPC classification number: C12Q1/66

Abstract: Briefly described, embodiments of this disclosure include polynucleotides that encode mutant Cnidarian luciferases that exhibit modulated properties as compared to the corresponding wild-type luciferases, and the modulated properties include at least one of: modulated stability; enhanced light output; and modulated emission maximum. Embodiments of the present disclosure also include polypeptides or fragments thereof encoded by the polynucleotides, constructs including the polynucleotide, expression cassettes, cells, methods of producing the polynucleotides and polypeptides, antibodies, transgenic cells and/or animals, kits, and the like.

Abstract translation: 简要描述，本公开的实施方案包括编码与相应的野生型萤光素酶相比表现出调节特性的突变型雀巢萤光素酶的多核苷酸，并且调节的性质包括以下至少一种：调节的稳定性; 增强光输出; 并调制发射最大值。 本公开的实施方案还包括由多核苷酸编码的多肽或其片段，包括多核苷酸的构建体，表达盒，细胞，产生多核苷酸和多肽的方法，抗体，转基因细胞和/或动物，试剂盒等。